Annual EBITDA:
-$282.37M+$189.67M(+40.18%)Summary
- As of today, ASND annual EBITDA is -$282.37 million, with the most recent change of +$189.67 million (+40.18%) on December 31, 2024.
- During the last 3 years, ASND annual EBITDA has risen by +$233.44 million (+45.26%).
- ASND annual EBITDA is now -3841.94% below its all-time high of $7.55 million, reached on December 31, 2013.
Performance
ASND EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
-$55.18M+$49.72M(+47.40%)Summary
- As of today, ASND quarterly EBITDA is -$55.18 million, with the most recent change of +$49.72 million (+47.40%) on June 1, 2025.
- Over the past year, ASND quarterly EBITDA has increased by +$83.56 million (+60.23%).
- ASND quarterly EBITDA is now -1164.78% below its all-time high of $5.18 million, reached on December 31, 2024.
Performance
ASND Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$256.36M+$83.56M(+24.58%)Summary
- As of today, ASND TTM EBITDA is -$256.36 million, with the most recent change of +$83.56 million (+24.58%) on June 1, 2025.
- Over the past year, ASND TTM EBITDA has increased by +$105.92 million (+29.24%).
- ASND TTM EBITDA is now -4561.50% below its all-time high of $5.75 million, reached on December 31, 2013.
Performance
ASND TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ASND EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +40.2% | +60.2% | +29.2% |
| 3Y3 Years | +45.3% | +62.3% | +50.6% |
| 5Y5 Years | -14.7% | +38.0% | +21.5% |
ASND EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +50.6% | -1164.8% | +63.0% | at high | +56.1% |
| 5Y | 5-Year | -14.7% | +50.6% | -1164.8% | +63.0% | at high | +56.1% |
| All-Time | All-Time | -3841.9% | +50.6% | -1164.8% | +63.0% | -4561.5% | +56.1% |
ASND EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$55.18M(+47.4%) | -$256.36M(+24.6%) |
| Mar 2025 | - | -$104.90M(-2124.2%) | -$339.92M(-19.9%) |
| Dec 2024 | -$282.37M(+40.2%) | $5.18M(+105.1%) | -$283.50M(+12.1%) |
| Sep 2024 | - | -$101.47M(+26.9%) | -$322.70M(+10.9%) |
| Jun 2024 | - | -$138.73M(-186.2%) | -$362.29M(+2.6%) |
| Mar 2024 | - | -$48.48M(-42.5%) | -$371.78M(+21.3%) |
| Dec 2023 | -$472.05M(+17.4%) | -$34.02M(+75.9%) | -$472.59M(+19.1%) |
| Sep 2023 | - | -$141.05M(+4.8%) | -$584.18M(-0.0%) |
| Jun 2023 | - | -$148.22M(+0.7%) | -$584.06M(-0.3%) |
| Mar 2023 | - | -$149.29M(-2.5%) | -$582.17M(-1.9%) |
| Dec 2022 | -$571.58M(-10.8%) | -$145.61M(-3.3%) | -$571.55M(-4.0%) |
| Sep 2022 | - | -$140.93M(+3.7%) | -$549.74M(-6.0%) |
| Jun 2022 | - | -$146.34M(-5.5%) | -$518.61M(-1.7%) |
| Mar 2022 | - | -$138.67M(-12.0%) | -$509.72M(+1.4%) |
| Dec 2021 | -$515.82M(-40.9%) | -$123.80M(-12.8%) | -$516.71M(-2.6%) |
| Sep 2021 | - | -$109.80M(+20.1%) | -$503.38M(-4.2%) |
| Jun 2021 | - | -$137.45M(+5.6%) | -$483.06M(-11.2%) |
| Mar 2021 | - | -$145.67M(-31.9%) | -$434.53M(-18.3%) |
| Dec 2020 | -$366.13M(-48.7%) | -$110.46M(-23.5%) | -$367.32M(-12.5%) |
| Sep 2020 | - | -$89.48M(-0.6%) | -$326.47M(-10.7%) |
| Jun 2020 | - | -$88.93M(-13.3%) | -$294.92M(-12.5%) |
| Mar 2020 | - | -$78.45M(-12.7%) | -$262.25M(-6.5%) |
| Dec 2019 | -$246.27M | -$69.61M(-20.2%) | -$246.23M(-13.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2019 | - | -$57.93M(-3.0%) | -$217.25M(-6.7%) |
| Jun 2019 | - | -$56.26M(+9.9%) | -$203.58M(-1.2%) |
| Mar 2019 | - | -$62.43M(-53.7%) | -$201.20M(-10.7%) |
| Dec 2018 | -$181.54M(-45.2%) | -$40.63M(+8.2%) | -$181.75M(-1.9%) |
| Sep 2018 | - | -$44.26M(+17.9%) | -$178.38M(-4.4%) |
| Jun 2018 | - | -$53.88M(-25.3%) | -$170.87M(-18.7%) |
| Mar 2018 | - | -$42.99M(-15.4%) | -$143.96M(-14.3%) |
| Dec 2017 | -$124.98M(-56.4%) | -$37.25M(-1.4%) | -$125.91M(-12.0%) |
| Sep 2017 | - | -$36.75M(-36.3%) | -$112.43M(-17.7%) |
| Jun 2017 | - | -$26.97M(-8.2%) | -$95.56M(-12.3%) |
| Mar 2017 | - | -$24.93M(-4.9%) | -$85.12M(-6.8%) |
| Dec 2016 | -$79.92M(-74.6%) | -$23.77M(-19.6%) | -$79.73M(-12.1%) |
| Sep 2016 | - | -$19.88M(-20.3%) | -$71.12M(-38.8%) |
| Jun 2016 | - | -$16.53M(+15.4%) | -$51.24M(-47.6%) |
| Mar 2016 | - | -$19.55M(-28.9%) | -$34.71M(-128.9%) |
| Dec 2015 | -$45.76M(-200.4%) | -$15.16M(-75.3%) | -$15.16M(-28.5%) |
| Dec 2014 | -$15.23M(-301.9%) | -$8.65M(-208.9%) | -$11.80M(-9554.6%) |
| Sep 2014 | - | -$2.80M(-1726.4%) | $124.80K(-97.7%) |
| Jun 2014 | - | $172.20K(+133.2%) | $5.40M(+3.3%) |
| Mar 2014 | - | -$519.20K(-115.9%) | $5.23M(-9.0%) |
| Dec 2013 | $7.55M(+203.1%) | $3.27M(+32.3%) | $5.75M(+132.3%) |
| Sep 2013 | - | $2.47M | $2.47M |
| Dec 2012 | $2.49M | - | - |
FAQ
- What is Ascendis Pharma A/S annual EBITDA?
- What is the all-time high annual EBITDA for Ascendis Pharma A/S?
- What is Ascendis Pharma A/S annual EBITDA year-on-year change?
- What is Ascendis Pharma A/S quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Ascendis Pharma A/S?
- What is Ascendis Pharma A/S quarterly EBITDA year-on-year change?
- What is Ascendis Pharma A/S TTM EBITDA?
- What is the all-time high TTM EBITDA for Ascendis Pharma A/S?
- What is Ascendis Pharma A/S TTM EBITDA year-on-year change?
What is Ascendis Pharma A/S annual EBITDA?
The current annual EBITDA of ASND is -$282.37M
What is the all-time high annual EBITDA for Ascendis Pharma A/S?
Ascendis Pharma A/S all-time high annual EBITDA is $7.55M
What is Ascendis Pharma A/S annual EBITDA year-on-year change?
Over the past year, ASND annual EBITDA has changed by +$189.67M (+40.18%)
What is Ascendis Pharma A/S quarterly EBITDA?
The current quarterly EBITDA of ASND is -$55.18M
What is the all-time high quarterly EBITDA for Ascendis Pharma A/S?
Ascendis Pharma A/S all-time high quarterly EBITDA is $5.18M
What is Ascendis Pharma A/S quarterly EBITDA year-on-year change?
Over the past year, ASND quarterly EBITDA has changed by +$83.56M (+60.23%)
What is Ascendis Pharma A/S TTM EBITDA?
The current TTM EBITDA of ASND is -$256.36M
What is the all-time high TTM EBITDA for Ascendis Pharma A/S?
Ascendis Pharma A/S all-time high TTM EBITDA is $5.75M
What is Ascendis Pharma A/S TTM EBITDA year-on-year change?
Over the past year, ASND TTM EBITDA has changed by +$105.92M (+29.24%)